Focus: Medical 21 is a biotechnology company focused on developing artificial grafts for cardiac bypass procedures, addressing a critical unmet need in cardiovascular surgery. The company operates as a specialized biotech player in the Minneapolis area with a narrow but clinically significant therapeutic focus.
Profile data last refreshed 55m ago · AI intelligence enriched 1mo ago
Growing — net +5 jobs in 30d
5 jobs added vs 0 removed. Steady team buildout.
Medical 21 presents an intriguing early-stage opportunity in a niche but critical indication, but extreme opacity around funding, clinical progress, and hiring activity introduces significant career risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Medical 21
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Medical 21's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles